DNA +4 afterhours.5:02PM Genentech: pivotal Herceptin data shows significant improvement in disease-free survival in breast cancer (DNA) 85.00 +0.30:Co announces that The New England Journal of Medicine published data from a joint interim analysis of two pivotal Phase III trials of Herceptin (trastuzumab) plus chemotherapy. The analysis showed that the addition of Herceptin significantly reduced the risk of breast cancer recurrence by 52% in women with early-stage, operable human epidermal growth factor receptor 2 (HER2)-positive breast cancer. After four years, 15% of women treated experienced disease recurrence, compared to 33% treated with chemotherapy alone. HER2-positive breast cancer is an especially aggressive form of the disease that affects 25% of women with breast cancer.
Best Of |
Favorites & Replies |
Start a New Board |
My Fool |
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ra